Illumina Competitors

Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Illumina and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Volatility and Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Earnings & Valuation

This table compares Illumina and Thermo Fisher Scientific's revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.4% of Illumina shares are owned by company insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Illumina and Thermo Fisher Scientific, as reported by MarketBeat.

Illumina currently has a consensus target price of $370.5789, indicating a potential downside of 7.12%. Thermo Fisher Scientific has a consensus target price of $527.05, indicating a potential upside of 6.92%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Summary

Thermo Fisher Scientific beats Illumina on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Agilent Technologies and Illumina's net margins, return on equity and return on assets.

Risk and Volatility

Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Agilent Technologies and Illumina's top-line revenue, earnings per share and valuation.

Illumina has lower revenue, but higher earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Agilent Technologies and Illumina, as reported by MarketBeat.com.

Agilent Technologies presently has a consensus price target of $106.1850, indicating a potential downside of 21.10%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's higher possible upside, analysts clearly believe Illumina is more favorable than Agilent Technologies.

Summary

Illumina beats Agilent Technologies on 9 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Mettler-Toledo International and Illumina's net margins, return on equity and return on assets.

Risk and Volatility

Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mettler-Toledo International and Illumina's top-line revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Mettler-Toledo International. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Mettler-Toledo International and Illumina, as reported by MarketBeat.com.

Mettler-Toledo International presently has a consensus price target of $971.3750, indicating a potential downside of 24.25%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Mettler-Toledo International.

Summary

Illumina beats Mettler-Toledo International on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Bio-Rad Laboratories and Illumina's net margins, return on equity and return on assets.

Risk and Volatility

Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Rad Laboratories and Illumina's top-line revenue, earnings per share and valuation.

Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Bio-Rad Laboratories and Illumina, as reported by MarketBeat.com.

Bio-Rad Laboratories presently has a consensus price target of $700.00, indicating a potential upside of 11.80%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Illumina.

Summary

Illumina beats Bio-Rad Laboratories on 8 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Waters and Illumina's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 1.5% of Waters shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Waters and Illumina, as reported by MarketBeat.com.

Waters presently has a consensus price target of $224.20, indicating a potential downside of 25.24%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Waters.

Valuation and Earnings

This table compares Waters and Illumina's top-line revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Waters on 9 of the 14 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Bio-Techne and Illumina's net margins, return on equity and return on assets.

Insider and Institutional Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bio-Techne has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bio-Techne and Illumina, as provided by MarketBeat.com.

Bio-Techne currently has a consensus target price of $367.50, suggesting a potential downside of 12.20%. Illumina has a consensus target price of $370.5789, suggesting a potential downside of 7.12%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than Bio-Techne.

Earnings and Valuation

This table compares Bio-Techne and Illumina's top-line revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Bio-Techne. Illumina is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Bio-Techne on 8 of the 14 factors compared between the two stocks.